BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD123 AND CD3, AND USES THEROF
The present invention is directed to sequence-optimized CD123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English Polish |
Published |
17.05.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention is directed to sequence-optimized CD123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies. |
---|---|
Bibliography: | Application Number: PL20140837858T |